UCB SA (UCB) - Financial and Strategic SWOT Analysis Review

Region:Europe

Author(s):

Product Code:GDPH33857FSA

Download Sample Report download
Buy the Full ReportStarting from $125
Published on

June 2019

Total pages

59

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $125

About the Report

About the Report

UCB SA (UCB)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases. It principally focuses on developing products for the treatment of central nervous system (CNS) and immunology related conditions. The company's key medicines include Cimzia for ankylosing spondylitis, axial spondylorthritis, Crohn's disease, psoriatic arthritis and rheumatoid arthritis; Neupro for Parkinson's disease and restless legs syndrome; and Vimpat, Keppra and Briviact for epilepsy. The company operates through subsidiaries in the US, Japan, China, Germany, Italy, Spain, France, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Belgium.

UCB SA Key Recent Developments

Jun 04,2019: UCB Boston research is advancing medical innovation

Mar 12,2019: Ireland to lead EUR7 million Parkinson's research project

Feb 28,2019: UCB full year report 2018: 2018 marks the fifth consecutive year of profitable growth, intensifying investment in UCB's strong pipeline

Feb 12,2019: UCB and Epilepsy Society partner to bring targeted treatments

Jan 18,2019: New online resource from AGA and the IBD parenthood project, in collaboration with multidisciplinary experts, provides guidance and dispels fears about pregnancy for women with IBD

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Products

Products

UCB SA, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Servier Laboratories Ltd

Novartis AG

Merck Serono SA

Johnson & Johnson

GlaxoSmithKline Plc

Eli Lilly and Co

Biotie Therapies Corp

Bausch Health Companies Inc

AstraZeneca Plc

Amgen Inc

Table of Contents

Table of Contents

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

UCB SA-Key Facts

UCB SA-Key Employees

UCB SA-Key Employee Biographies

UCB SA-Major Products and Services

UCB SA-History

UCB SA-Company Statement

UCB SA-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Joint Venture

Section 2-Company Analysis

Company Overview

UCB SA-Business Description

Product Category: Established Brands

Overview

Performance

Product Category: Immunology

Overview

Performance

Product Category: Neurology

Overview

Performance

Geographical Segment: Europe

Target Markets

Performance

Geographical Segment: International Markets

Performance

Geographical Segment: US

Performance

R&D Overview

UCB SA-Corporate Strategy

UCB SA-SWOT Analysis

SWOT Analysis-Overview

UCB SA-Strengths

UCB SA-Weaknesses

UCB SA-Opportunities

UCB SA-Threats

UCB SA-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Capital Market Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

UCB SA, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

UCB SA, Recent Deals Summary

Section 5-Company's Recent Developments

Jun 04, 2019: UCB Boston research is advancing medical innovation

Mar 12, 2019: Ireland to lead EUR7 million Parkinson's research project

Feb 28, 2019: UCB full year report 2018: 2018 marks the fifth consecutive year of profitable growth, intensifying investment in UCB's strong pipeline

Feb 12, 2019: UCB and Epilepsy Society partner to bring targeted treatments

Jan 18, 2019: New online resource from AGA and the IBD parenthood project, in collaboration with multidisciplinary experts, provides guidance and dispels fears about pregnancy for women with IBD

Dec 05, 2018: UCB to invest in UK healthcare innovations

Oct 30, 2018: UCB first nine months interim report 2018: UCB tracking well towards full year financial outlook

Oct 24, 2018: UCB brings HR to the cloud with SAP successFactors solutions

Oct 05, 2018: New online patent-search tool launched

Sep 05, 2018: New approach accelerates drug discovery

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List of Figure

List of Figures

UCB SA, Performance Chart (2014-2018)

UCB SA, Ratio Charts

UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

UCB SA, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List of Table

List of Tables

UCB SA, Key Facts

UCB SA, Key Employees

UCB SA, Key Employee Biographies

UCB SA, Major Products and Services

UCB SA, History

UCB SA, Subsidiaries

UCB SA, Joint Venture

UCB SA, Key Competitors

UCB SA, Ratios based on current share price

UCB SA, Annual Ratios

UCB SA, Annual Ratios (Cont...1)

UCB SA, Annual Ratios (Cont...2)

UCB SA, Interim Ratios

UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

UCB SA, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

UCB SA, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022